This study is currently not recruiting participants.

Expanded-Access Single Named-Patient Guidance Document For The Use Of Bms 790052 (Daclatasvir; Dcv) In Combination With Sofosbuvir (Sof) For The Treatent Of A Patient With Recurrent Hepatitis C Virus (Hcv) Infection

Investigating Treatment Access for Chronic Hepatitis C Virus

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to provide access to daclatasvir to a single named patient who is infected with chronic hepatitis C virus (HCV).

Detailed description of study

The purpose of this study is to provide access to daclatasvir to a single named patient who is infected with chronic hepatitis C virus (HCV).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hepatitis C Virus
  • Age: 100 years or below
  • Gender: All

This study investigates the provision of access to an investigational medication for a single patient with chronic hepatitis C virus (HCV). Hepatitis C is a liver infection caused by the hepatitis C virus, which can lead to liver damage over time.

The study involves providing the investigational medication to the patient to manage their condition. It aims to evaluate the effects and feasibility of this approach in treating chronic HCV.

  • Who can participate: This study is designed for a single named patient with chronic hepatitis C virus infection. No additional age criteria or eligibility factors apply.
  • Study details: The participant will receive an investigational medication to manage their HCV condition.
Updated on 19 Feb 2024. Study ID: 1404778834

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team